Biopharma Quarterly Dealmaking Statistics, Q2 2015
A look at financing, M&A and alliance activity April–June 2015
Q2 biopharma financing reached $15.4 billion, a slight increase over the previous quarter; leading the M&A activity was CVS' $11.8 billion buy of Omnicare; and AstraZeneca and Juno were the two most active dealmakers in cancer immunotherapy, a popular therapeutic focus of Q2 alliances.